Merck opens €300m South Korea plant for regional biopharma
The 44,500-square-meter Daejeon facility produces dry cell culture media and process liquids to cut lead times for contract manufacturers across the Asia-Pacific region.
MOBy Mina Okoro, Supply chain editor··Updated October 31, 2026·3 min read
ShareLinkedInXWhatsAppEmailTechnicians in protective gear operate stainless steel machinery inside the bioprocessing production center in Daejeon. (AI-generated image)
Merck KGaA opened its 300 million euro ($334 million) bioprocessing production center in Daejeon, South Korea, on Oct. 29, 2026, anchoring regional supply for critical biologic drug inputs.
The 44,500-square-meter complex in the Dungok district represents the largest life science investment that Merck has made in the Asia-Pacific region. The facility sits 140 kilometers south of Seoul within the International Science and Business Belt.
The documents behind this briefing are linked above. East Asia Brief produces its English text with AI assistance under human editorial review, and does not translate or republish other outlets' articles. See our methodology and AI policy. Spotted an error? Tell us.
Supply chain editor — Mina Okoro builds the impact maps that connect East Asian developments to buyers in North America and Europe, and edits the Asia Compare desk.
